A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma

Results of long term follow-up

Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Haruhito Kamei, Kenichi Gemba, Katsuyoshi Sakae, Yoshio Hiraki, Shunkichi Hiraki, Yoshihiko Segawa, Mine Harada

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to compare HYB with CAV-PVP sequential chemotherapy (SEQ). METHODS. Patients in the HYB group received the 3-drug CAV combination on Day 1 and the 2-drug PVP combination on Day 8, repeated every 4 weeks for up to 6 cycles. Patients in the SEQ group received 3 cycles each of CAV and PVP sequentially every 4 weeks, delivered on Days 1 and 8. All responding patients with limited disease (LD) received thoracic irradiation (50 gray) after chemotherapy. RESULTS. Between April 1988 and October 1992, 129 patients were evaluated fully. There were no significant differences in the treatment outcome between patients in the HYB and SEQ groups in terms of the complete response rate (59% for LD patients and 21% for extensive disease [ED] patients in the HYB group vs. 45% for LD patients and 16% for ED patients in the SEQ group), or median survival time (17.9 months for LD patients and 9.7 months for ED patients in the HYB group vs. 20.6 months for LD patients and 12.2 months for ED patients in the SEQ group). CONCLUSIONS. Hybrid CAV-PVP therapy is effective for the treatment of SCLC, but appears to be no better than sequential therapy with the same regimen.

Original languageEnglish
Pages (from-to)283-290
Number of pages8
JournalCancer
Volume83
Issue number2
DOIs
Publication statusPublished - Jul 15 1998

Fingerprint

Small Cell Lung Carcinoma
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Drug Therapy
Therapeutics
Thoracic Diseases
Drug Combinations

Keywords

  • Chemotherapy
  • Dose-intensity
  • Drug resistance
  • Small cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up. / Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Kamei, Haruhito; Gemba, Kenichi; Sakae, Katsuyoshi; Hiraki, Yoshio; Hiraki, Shunkichi; Segawa, Yoshihiko; Harada, Mine.

In: Cancer, Vol. 83, No. 2, 15.07.1998, p. 283-290.

Research output: Contribution to journalArticle

@article{d839ab62b3184d78996f436b055b74cd,
title = "A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: Results of long term follow-up",
abstract = "BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to compare HYB with CAV-PVP sequential chemotherapy (SEQ). METHODS. Patients in the HYB group received the 3-drug CAV combination on Day 1 and the 2-drug PVP combination on Day 8, repeated every 4 weeks for up to 6 cycles. Patients in the SEQ group received 3 cycles each of CAV and PVP sequentially every 4 weeks, delivered on Days 1 and 8. All responding patients with limited disease (LD) received thoracic irradiation (50 gray) after chemotherapy. RESULTS. Between April 1988 and October 1992, 129 patients were evaluated fully. There were no significant differences in the treatment outcome between patients in the HYB and SEQ groups in terms of the complete response rate (59{\%} for LD patients and 21{\%} for extensive disease [ED] patients in the HYB group vs. 45{\%} for LD patients and 16{\%} for ED patients in the SEQ group), or median survival time (17.9 months for LD patients and 9.7 months for ED patients in the HYB group vs. 20.6 months for LD patients and 12.2 months for ED patients in the SEQ group). CONCLUSIONS. Hybrid CAV-PVP therapy is effective for the treatment of SCLC, but appears to be no better than sequential therapy with the same regimen.",
keywords = "Chemotherapy, Dose-intensity, Drug resistance, Small cell lung carcinoma",
author = "Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Haruhito Kamei and Kenichi Gemba and Katsuyoshi Sakae and Yoshio Hiraki and Shunkichi Hiraki and Yoshihiko Segawa and Mine Harada",
year = "1998",
month = "7",
day = "15",
doi = "10.1002/(SICI)1097-0142(19980715)83:2<283::AID-CNCR12>3.0.CO;2-P",
language = "English",
volume = "83",
pages = "283--290",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma

T2 - Results of long term follow-up

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Kamei, Haruhito

AU - Gemba, Kenichi

AU - Sakae, Katsuyoshi

AU - Hiraki, Yoshio

AU - Hiraki, Shunkichi

AU - Segawa, Yoshihiko

AU - Harada, Mine

PY - 1998/7/15

Y1 - 1998/7/15

N2 - BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to compare HYB with CAV-PVP sequential chemotherapy (SEQ). METHODS. Patients in the HYB group received the 3-drug CAV combination on Day 1 and the 2-drug PVP combination on Day 8, repeated every 4 weeks for up to 6 cycles. Patients in the SEQ group received 3 cycles each of CAV and PVP sequentially every 4 weeks, delivered on Days 1 and 8. All responding patients with limited disease (LD) received thoracic irradiation (50 gray) after chemotherapy. RESULTS. Between April 1988 and October 1992, 129 patients were evaluated fully. There were no significant differences in the treatment outcome between patients in the HYB and SEQ groups in terms of the complete response rate (59% for LD patients and 21% for extensive disease [ED] patients in the HYB group vs. 45% for LD patients and 16% for ED patients in the SEQ group), or median survival time (17.9 months for LD patients and 9.7 months for ED patients in the HYB group vs. 20.6 months for LD patients and 12.2 months for ED patients in the SEQ group). CONCLUSIONS. Hybrid CAV-PVP therapy is effective for the treatment of SCLC, but appears to be no better than sequential therapy with the same regimen.

AB - BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to compare HYB with CAV-PVP sequential chemotherapy (SEQ). METHODS. Patients in the HYB group received the 3-drug CAV combination on Day 1 and the 2-drug PVP combination on Day 8, repeated every 4 weeks for up to 6 cycles. Patients in the SEQ group received 3 cycles each of CAV and PVP sequentially every 4 weeks, delivered on Days 1 and 8. All responding patients with limited disease (LD) received thoracic irradiation (50 gray) after chemotherapy. RESULTS. Between April 1988 and October 1992, 129 patients were evaluated fully. There were no significant differences in the treatment outcome between patients in the HYB and SEQ groups in terms of the complete response rate (59% for LD patients and 21% for extensive disease [ED] patients in the HYB group vs. 45% for LD patients and 16% for ED patients in the SEQ group), or median survival time (17.9 months for LD patients and 9.7 months for ED patients in the HYB group vs. 20.6 months for LD patients and 12.2 months for ED patients in the SEQ group). CONCLUSIONS. Hybrid CAV-PVP therapy is effective for the treatment of SCLC, but appears to be no better than sequential therapy with the same regimen.

KW - Chemotherapy

KW - Dose-intensity

KW - Drug resistance

KW - Small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0032528220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032528220&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980715)83:2<283::AID-CNCR12>3.0.CO;2-P

DO - 10.1002/(SICI)1097-0142(19980715)83:2<283::AID-CNCR12>3.0.CO;2-P

M3 - Article

VL - 83

SP - 283

EP - 290

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -